Gain Therapeutics, Inc. (GANX) Dividend History

Company News

• Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

  Gain Therapeutics presented positive Phase 1 data for its lead drug candidate GT-02287, which showed an increase in GCase activity in healthy volunteers, supporting its potential as a disease-modifying treatment for Parkinson's disease.

  GlobeNewswire Inc.
• Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease

  Gain Therapeutics, a clinical-stage biotechnology company, will host a webinar to discuss positive results from a Phase 1 study of its lead drug candidate GT-02287 for Parkinson's disease and the design of an upcoming Phase 1b trial.

  GlobeNewswire Inc.
• Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

  Gain Therapeutics announced that it will present preclinical data on its lead drug candidate GT-02287 for the treatment of Parkinson's disease, including two late-breaking posters, at the Neuroscience 2024 conference.

  GlobeNewswire Inc.
• 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Autonomix Medical (NASDAQ:AMIX), Absci ... - Benzinga

  Several healthcare stocks saw significant price movements in Thursday's pre-market session, with notable gainers including Autonomix Medical, Inspire Veterinary, and Salarius Pharmaceuticals, while Gain Therapeutics, Senti Biosciences, and Aspira Womens Health declined.

  Benzinga

  Featured Companies: AMIX IVP SLRX SNTI
• Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

  BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open.

  GlobeNewswire Inc.